BLUE BELL, Pa., March 12, 2014 /PRNewswire/ -- Inovio
Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that it will
host a conference call and live webcast to report its fourth
quarter and year end 2013 financial results on Monday, March 17, 2014 at 8:30 a.m. ET. Management will provide an update
on the company, discuss fourth quarter and year end results, and
discuss expectations for 2014.
The audio presentation will be broadcast online at
http://www.investorcalendar.com/IC/CEPage.asp?ID=172460. Investors
can also access the presentation through the "Webcast" tab on
Inovio's home page at www.inovio.com. This is a listen-only event
but will include a live Q&A with analysts.
A replay of the conference call will be available beginning two
hours after the call until April 17,
2014. To access the replay by telephone, dial 877-660-6853
(domestic) or 201-612-7415 (international) and use passcode
13578005. The replay will also be available as a webcast and can be
found under the "Webcast" tab on Inovio's website.
About Inovio Pharmaceuticals, Inc.
Inovio is revolutionizing vaccines to prevent and treat today's
cancers and challenging infectious diseases. Its SynCon® DNA-based
immunotherapies and vaccines, in combination with its proprietary
electroporation delivery, are generating best-in-class immune
responses, with therapeutic T-cell responses exceeding other
technologies in terms of magnitude, breadth, and response rate.
Human data to date have shown a favorable safety profile. Inovio's
lead product, a therapeutic against HPV-caused pre-cancers and
cancers, is in phase II. Other phase I and preclinical programs
target prostate, breast, and lung cancers as well as hepatitis,
HIV, and influenza. Partners and collaborators include Roche, the
University of Pennsylvania, NIH, HIV
Vaccines Trial Network, National Cancer Institute, U.S. Military
HIV Research Program, University of Southampton, US Dept. of
Homeland Security, University of
Manitoba and PATH Malaria Vaccine Initiative. More
information is available at www.inovio.com.
This press release contains certain forward-looking
statements relating to our business, including our plans to develop
electroporation-based drug and gene delivery technologies and DNA
vaccines and our capital resources. Actual events or results may
differ from the expectations set forth herein as a result of a
number of factors, including uncertainties inherent in pre-clinical
studies, clinical trials and product development programs
(including, but not limited to, the fact that pre-clinical and
clinical results referenced in this release may not be indicative
of results achievable in other trials or for other indications,
that the studies or trials may not be successful or achieve the
results desired, that pre-clinical studies and clinical trials may
not commence or be completed in the time periods anticipated, that
results from one study may not necessarily be reflected or
supported by the results of other similar studies and that results
from an animal study may not be indicative of results achievable in
human studies), the availability of funding to support continuing
research and studies in an effort to prove safety and efficacy of
electroporation technology as a delivery mechanism or develop
viable DNA vaccines, the adequacy of our capital resources, the
availability or potential availability of alternative therapies or
treatments for the conditions targeted by the company or its
collaborators, including alternatives that may be more efficacious
or cost-effective than any therapy or treatment that the company
and its collaborators hope to develop, evaluation of potential
opportunities, issues involving product liability, issues involving
patents and whether they or licenses to them will provide the
company with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or
defensible or infringe or allegedly infringe on rights of others or
can withstand claims of invalidity and whether the company can
finance or devote other significant resources that may be necessary
to prosecute, protect or defend them, the level of corporate
expenditures, assessments of the company's technology by potential
corporate or other partners or collaborators, capital market
conditions, the impact of government healthcare proposals and other
factors set forth in our Annual Report on Form 10-K for the year
ended December 31, 2012, our Form
10-Q for the quarter ended September 30,
2013, and other regulatory filings from time to time. There
can be no assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio
Pharmaceuticals, 858-410-3101 bhertel@inovio.com
Media: Jeff Richardson, Inovio
Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Logo -
http://photos.prnewswire.com/prnh/20131118/LA18202LOGO
SOURCE Inovio Pharmaceuticals, Inc.